| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Atossa Therapeutics, Inc.$1.88
+0.13 (+7.34%)
C 45Pipeline Score Fair Value Pharma · Clinical
Market Cap
41.77 M
EPS
-4.37
P/E Ratio
-1.11 $
Value Trade
212.74 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.78 M
Operating CF
-9.58 M
Total Assets
37.94 M
Total Liabilities
7.46 M
Equity
30.49 M
D/E Ratio
12,345
-2.94 %
Week
-15.5 %
1 Month
13.24 %
3 Month
-56.1 %
6 Month
-89.86 %
5 Year
-99.96 %
All Time
Cash Data
Cash Position
31.72 M
Monthly Burn
3.19 M
Runway
8.3 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
377.88 K
52 Week Range
3.76 - 19.35
% held by Insiders
1.76 %
% held by Institutions
16.23 %
Enterprise Value
9.94 M
Total Shares
8.61 M
Short %
6.95 %
Float Shares
7.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C45
Pipeline Score $100M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored2.4x
rNPV / MCap Top 69%
Micro Cap (rank 282 of 905)
Percentile RankAtossa Therapeutics, Inc. carries a moderate pipeline score (45/100), with $3.9B risk-adjusted pipeline value, led by -endoxifen in Breast Neoplasms (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| endoxifen Small molecule | Mammographic Breast Density | Phase 2 | NCT04616430 | 52% | $3.5B | COMPLETED | 90 | - | - | Sep 4, 2019 | - | Jul 12, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
(Z)-endoxifen | metastatic breast cancer | Phase 2 | 2025-07-29 | |||
(Z)-endoxifen | metastatic breast cancer | Phase 2 | 2025-07-29 | |||
(Z)-endoxifen | metastatic breast cancer | Phase 2 | 2025-07-29 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATOS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ATOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATOS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATOS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ATOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATOSAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Atossa Therapeutics has successfully closed a registered direct offering, raising $4.5 million in gross proceeds. The offering includes Series A and Series B warrants, which could potentially yield an additional $12 million if fully exercised. The funds will be allocated towards clinical development and general corporate purposes. The company emphasizes that there are no guarantees regarding the exercise of the warrants.
Read more →ATOSAtossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
Atossa Therapeutics has announced a registered direct offering to raise up to $16.5 million, consisting of $4.5 million upfront and potential additional proceeds from warrants. The offering is aimed at funding clinical development and general corporate purposes. The closing is expected around June 12, 2026, pending customary conditions.
Read more →ATOSAtossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Atossa Therapeutics announced the acceptance of two abstracts for presentation at the ASCO 2026 Annual Meeting, highlighting the efficacy of (Z)-endoxifen in treating ER-positive breast cancer with ESR1 mutations. Preclinical results indicated significant estrogen receptor inhibition, suggesting (Z)-endoxifen's potential role in overcoming endocrine resistance. Additionally, the ongoing EVANGELINE Phase 2 trial is evaluating its effectiveness combined with goserelin as neoadjuvant therapy for premenopausal women. This research underscores Atossa's commitment to addressing important treatment gaps in breast cancer care.
Read more →ATOSAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Atossa Therapeutics announced the acceptance of a manuscript detailing the potential of (Z)-endoxifen to modulate utrophin pathways in Duchenne Muscular Dystrophy (DMD). The review highlights how (Z)-endoxifen may support muscle stabilization and repair. The company plans further preclinical evaluations and biomarker development to explore its therapeutic potential.
Read more →ATOSAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Atossa Therapeutics will host a virtual event featuring Dr. Laura Esserman to discuss the development of (Z)-endoxifen for ER-positive breast cancer. The event will cover recent clinical data, including the I-SPY2 study and biomarker findings. Dr. Esserman, a leader in breast cancer research, will provide insights into the therapy's potential as an endocrine treatment across various settings.
Read more →ATOSAtossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics reported its financial results for Q1 2026, highlighting progress in the development of (Z)-endoxifen for breast cancer and rare diseases. The company received FDA designations for its drug in Duchenne Muscular Dystrophy and McCune-Albright Syndrome. Despite a strong balance sheet, operating expenses and net losses have increased compared to the previous year.
Read more →ATOSAtossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Atossa Therapeutics announced the publication of the KARISMA Endoxifen trial results, which demonstrated that low-dose Endoxifen significantly reduces mammographic breast density in healthy premenopausal women. The Phase 2 study showed reductions comparable to tamoxifen, with a favorable tolerability profile. The findings suggest Endoxifen could be a promising option for breast cancer risk reduction.
Read more →ATOSAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Atossa Therapeutics has received FDA Rare Pediatric Disease designation for (Z)-endoxifen, aimed at treating McCune-Albright Syndrome in females. This designation not only validates the drug's potential beyond oncology but also opens up opportunities for a Priority Review Voucher upon approval. The company emphasizes its commitment to addressing the significant unmet medical needs associated with this rare pediatric disorder.
Read more →ATOSAtossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics reported its financial results for Q4 and the year ending December 31, 2025. The company highlighted progress in its (Z)-endoxifen development and received FDA designations that may expedite its review process. Atossa is also focusing on commercialization efforts while managing increased operating expenses and decreased interest income.
Read more →ATOSAtossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Atossa Therapeutics has announced the addition of Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. to its clinical leadership team. Dr. Theall will serve as Medical Director for Breast Oncology while Dr. Giwa will take on the role of Medical Director for Rare Diseases. Both executives bring extensive experience from their respective fields, which is expected to enhance Atossa's clinical development strategy for its lead product, (Z)-endoxifen, across various therapeutic areas. The company aims to meet key clinical and regulatory milestones with this strengthened team.
Read more →ATOSAtossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Atossa Therapeutics presented promising findings on (Z)-endoxifen at the MDA Clinical & Scientific Conference. The preclinical study indicates that (Z)-endoxifen may restore muscle performance and reduce damage biomarkers in dystrophic mice, suggesting its potential as a new treatment for Duchenne muscular dystrophy. The company emphasizes the need for further clinical investigation.
Read more →ATOSAtossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Therapeutics provided a shareholder update highlighting its progress in 2025, particularly in advancing (Z)-endoxifen for breast cancer and other rare diseases. The company completed a Type C meeting with the FDA, clarifying potential expedited pathways for development. Despite pausing investment in metastatic breast cancer trials, Atossa is focusing on strengthening its intellectual property and preparing for future commercialization. The company enters 2026 with a clear regulatory roadmap and a strong financial position.
Read more →ATOSAtossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Atossa Therapeutics has reaffirmed its strong market position for (Z)-endoxifen in treating Duchenne Muscular Dystrophy (DMD) following Congress's reauthorization of the Rare Pediatric Disease Priority Review Voucher Program. This designation allows Atossa to qualify for a future PRV upon FDA approval, enhancing its development strategy. The company expresses optimism about the drug's potential as a treatment option for DMD, addressing significant unmet medical needs.
Read more →ATOSAtossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Atossa Therapeutics' CEO, Dr. Steven Quay, has been named one of the Top 50 Healthcare Technology CEOs of 2025. This accolade highlights his leadership in advancing innovative therapies, particularly (Z)-endoxifen, a treatment for breast cancer. Under his guidance, Atossa focuses on precision-based therapies and fostering a culture of innovation.
Read more →ATOSAtossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Atossa Therapeutics has received Orphan Drug Designation from the FDA for (Z)-Endoxifen, aimed at treating Duchenne muscular dystrophy (DMD). This designation, along with a previous Rare Pediatric Disease designation, marks a significant milestone for the company. Atossa plans to continue its engagement with the FDA as it advances the drug's development.
Read more →ATOSAtossa Therapeutics Receives FDA “Study May Proceed” Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer SEATTLE, WA
Atossa Therapeutics has received a 'Study May Proceed' letter from the FDA for its investigational new drug application concerning (Z)-Endoxifen aimed at treating metastatic breast cancer. This marks a significant milestone for Atossa as it seeks to broaden the use of this potentially effective therapy, particularly for tumors that may be resistant to existing treatments. The drug is a selective estrogen receptor modulator/degrader with a distinct safety profile, and Atossa is optimistic about its prospects in both oncology and rare diseases. Atossa's (Z)-Endoxifen is not yet approved for any indication, but the company is moving forward with clinical evaluations.
Read more →ATOSAtossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Atossa Therapeutics has received a 'Study May Proceed' letter from the FDA for its investigational new drug application of (Z)-Endoxifen in treating metastatic breast cancer. This approval represents a significant regulatory milestone, indicating the potential for the drug to be effective against tumors resistant to standard therapies. (Z)-Endoxifen is noted for its favorable safety profile and unique pharmacology. The company aims to advance its clinical investigation following this positive regulatory feedback.
Read more →ATOSAtossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
Atossa Therapeutics has been awarded the 2025 Clinical Trials Arena Excellence Award for its advancements in precision endocrine therapy, particularly for its lead product (Z)-endoxifen. This therapy is being evaluated for various applications in breast cancer and Duchenne Muscular Dystrophy. The award highlights Atossa's commitment to innovation and its integrated approach to clinical development.
Read more →ATOSAtossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
Atossa Therapeutics presented four clinical trial updates on (Z)-endoxifen at the 2025 San Antonio Breast Cancer Symposium. The updates highlight the drug's potential in treating breast cancer and reducing risks associated with high mammographic density. The company emphasizes its commitment to advancing clinical programs and improving patient outcomes through innovative treatment strategies.
Read more →ATOSAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
Atossa Therapeutics has received FDA Rare Pediatric Disease designation for (Z)-Endoxifen, aimed at treating Duchenne Muscular Dystrophy (DMD). This designation may allow Atossa to qualify for a Priority Review Voucher upon approval, enhancing their regulatory interactions. The company believes this milestone validates the potential of (Z)-Endoxifen as a treatment option for DMD, addressing significant unmet medical needs.
Read more →ATOSAtossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
Atossa Therapeutics announced the issuance of U.S. Patent No. 12,479,790 B2, which covers enteric oral formulations of (Z)-endoxifen and methods for treating hormone-dependent breast disorders. This patent enhances Atossa's intellectual property portfolio and supports its strategy for developing (Z)-endoxifen across various breast cancer treatment stages. The company aims to leverage this patent for future commercialization and clinical trials.
Read more →ATOSAtossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Atossa Therapeutics has completed a Type C meeting with the FDA to discuss regulatory strategies for (Z)-endoxifen in breast cancer treatment. The FDA's feedback may facilitate expedited pathways for clinical development across various settings, including metastatic and neoadjuvant treatments. The company aims to leverage this guidance to accelerate its development timeline and pursue multiple regulatory endpoints.
Read more →ATOSInsilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
Insilico Medicine and Atossa Therapeutics have published a study in Nature Scientific Reports, exploring the potential of (Z)-endoxifen as a therapeutic candidate for glioblastoma multiforme. The research utilized AI-powered methods to analyze over 900 cancer indications, identifying GBM as a promising target. Laboratory results support endoxifen's efficacy in suppressing GBM cell proliferation and inducing apoptosis.
Read more →ATOSAtossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
Atossa Therapeutics announced promising findings regarding (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) and related pathologies in female carriers. A peer-reviewed article outlines its multi-pathway efficacy, while an upcoming presentation will focus on symptomatic female carriers. The company aims to advance clinical studies to assess safety and efficacy.
Read more →ATOSAtossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics reported its third quarter 2025 financial results, highlighting progress in the development of (Z)-endoxifen for breast cancer. The company is focused on filing an IND and has appointed key leadership to drive this initiative. Despite increased operating expenses and a decrease in interest income, Atossa remains optimistic about its financial position and upcoming milestones.
Read more →ATOSAtossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Atossa Therapeutics has announced that four abstracts on (Z)-endoxifen have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium. The studies will focus on the drug's potential in advancing breast cancer treatment and prevention. The presentations are scheduled for December 11 and 12, 2025, showcasing various aspects of (Z)-endoxifen's efficacy.
Read more →ATOSAtossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
Atossa Therapeutics announced progress in its RECAST trial for ductal carcinoma in situ (DCIS) at the Early Detection Research Conference. The trial aims to determine which hormone receptor-positive DCIS patients can safely avoid surgery through active surveillance and novel endocrine therapies. Enrollment is ongoing, with 50 patients enrolled towards a target of 400.
Read more →ATOSAtossa Therapeutics to Present at the Maxim Growth Summit 2025
Atossa Therapeutics will present at the Maxim Growth Summit on October 22-23, 2025, in New York City. CEO Steven Quay will lead discussions and is available for one-on-one investor meetings. The company aims to attract new investors and provide updates on its innovative breast cancer treatments.
Read more →ATOSAtossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Atossa Therapeutics has appointed Mark Daniel as Chief Financial Officer to guide the company's financial strategy as it prepares for commercial operations with (Z)-endoxifen. Daniel brings over 25 years of experience in life sciences finance, focusing on revenue forecasting and capital management. His leadership is expected to enhance Atossa's operational readiness and strategic financing as the company transitions from clinical development to commercialization.
Read more →ATOSAtossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
Atossa Therapeutics has announced significant progress in its global patent strategy for Z-endoxifen, including the issuance of a patent in Israel. The patent, which covers high-purity enteric formulations and manufacturing methods, is part of Atossa's strategy to support its clinical and commercial plans. Additionally, Atossa received a Certificate of Patent Renewal for the Israeli patent, reinforcing its commitment to managing its intellectual property effectively. The company aims to harness these protections to deliver Z-endoxifen to patients and enhance shareholder value.
Read more →ATOSAtossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
Atossa Therapeutics has announced amendments to its Phase 2 EVANGELINE trial for (Z)-endoxifen, targeting early-stage ER+/HER2- breast cancer. The changes are designed to lower future study costs and enable quicker objective readouts, aligning with Atossa's 2025-2026 development strategy focused on NDA-enabling activities. This streamlined approach will involve a reduction in patient total from 214 to 40-65 and emphasizes maintaining rigorous safety oversight. The company aims to allocate capital efficiently to support promising clinical results and regulatory submissions.
Read more →ATOSAtossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
Atossa Therapeutics has appointed Janet R. Rea as the new Senior Vice President of R&D to enhance the development of (Z)-endoxifen, a key product in their pipeline aimed at breast cancer treatment. Ms. Rea, known for her successful track record in securing regulatory approvals, will oversee late-stage clinical programs as Atossa prepares for upcoming FDA submissions. Her previous experience at Atossa and other biopharma companies positions her well to advance their initiatives and address critical clinical needs in breast cancer treatment. The company aims to deliver innovative therapies while contributing to improved patient outcomes.
Read more →ATOSAtossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
Atossa Therapeutics has appointed CORE IR to enhance its investor relations and communications. This partnership aims to improve shareholder engagement and increase market visibility for the company. CEO Dr. Steven Quay expressed optimism about the collaboration, emphasizing its importance in articulating Atossa's value proposition. CORE IR will provide a range of services to support these initiatives.
Read more →ATOSAtossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE ȁ
Atossa Therapeutics has announced its regulatory strategy to accelerate the development of low-dose (Z)-endoxifen aimed at breast cancer risk reduction. A Type C meeting with the FDA has been requested to align on the requirements for a New Drug Application. By potentially streamlining the approval process, the company could significantly reduce costs and timelines. The market for low-dose (Z)-endoxifen is projected to be substantial, given the number of women currently using tamoxifen and other therapies.
Read more →ATOSAtossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
Atossa Therapeutics, Inc. has announced that CEO Dr. Steven Quay will participate in a fireside chat at the 27th Annual H.C. Wainwright Global Investment Conference. The discussion will center around the company’s clinical progress and the pipeline for their lead product candidate, (Z)-endoxifen, which may provide a new solution for breast cancer prevention and treatment. Dr. Quay will also share updates regarding recent positive feedback from regulatory advisors that may help to expedite the company's development efforts. The event will be webcast live, with replay options available for investors.
Read more →ATOSAtossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
Atossa Therapeutics has chosen PSI as the Contract Research Organization to manage its pivotal dose-ranging study of (Z)-endoxifen, aimed at treating metastatic breast cancer. The Phase 2 study was developed with input from the FDA and will assess safety and preliminary efficacy, with patient enrollment starting post-IND filing expected in Q4 2025. With topline results anticipated in 2026, the study positions Atossa for a transition into Phase 3 development, aiming to provide new hope for patients with limited treatment options.
Read more →ATOSAtossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA In
Atossa Therapeutics reported strong progress in its development of (Z)-endoxifen for metastatic breast cancer, receiving positive feedback from the FDA. The agency has cleared the path for the company to file an Investigational New Drug (IND) application without the need for additional toxicity studies. Furthermore, the results from the I-SPY2 trial indicated significant efficacy, with improvements in key biomarkers among participants. The company is well-positioned financially and is focused on upcoming milestones, including the IND submission targeted for Q4 2025.
Read more →ATOSAtossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
Atossa Therapeutics has received positive feedback from the FDA regarding its proposed dose optimization trial for (Z)-endoxifen, aimed at treating ER+/HER2- metastatic breast cancer. The FDA affirmed key elements of the company's clinical development plan and deemed existing nonclinical data sufficient to proceed with the trial, enabling a potential Investigational New Drug (IND) submission by the end of 2025. The company plans to announce further details about the trial design and patient population in the coming weeks, reflecting its strong strategic momentum in this area. Atossa's (Z)-endoxifen shows promise with its unique formulation and potential efficacy in patients with limited treatment options.
Read more →ATOSAtossa Therapeutics to Present at the Jefferies Global Healthcare Conference
Atossa Therapeutics, Inc. has announced that its President and CEO, Dr. Steven Quay, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The event will provide an opportunity for the company to share its innovative approaches in breast cancer treatment, particularly through its lead product candidate, (Z)-endoxifen. A live webcast of the presentation will be available on the Atossa website, and the session will be archived for 30 days for broader access.
Read more →ATOSAtossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
Atossa Therapeutics reported successful results from its I-SPY 2 pilot sub-study, demonstrating that low-dose (Z)-endoxifen is bioactive in treating ER+/HER2- breast cancer. A high feasibility rate was achieved with 95% of participants completing dosing, alongside significant tumor shrinkage and a well-tolerated safety profile. Despite the absence of complete pathologic response among participants, the study established a foundation for further trials with higher doses intended to enhance pathological outcomes. Atossa aims to leverage these findings to develop (Z)-endoxifen as an effective alternative in advanced breast cancer treatment.
Read more →ATOSAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellec
Atossa Therapeutics recently announced its financial results for the first quarter of 2025, highlighting a strategic focus on advancing (Z)-endoxifen for metastatic breast cancer. The company strengthened its intellectual property portfolio with the issuance of three new U.S. patents, expanding its claims related to (Z)-endoxifen to over 200. Despite ending the quarter with no revenue, Atossa reported substantial cash reserves and is committed to addressing unmet medical needs in breast cancer treatment.
Read more →ATOSAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
Atossa Therapeutics announced the issuance of U.S. Patent No. 12,281,056, which covers 58 claims related to its (Z)-endoxifen formulations. This patent enhances Atossa's intellectual property portfolio and supports its mission to develop innovative treatments for breast cancer. The company is focused on advancing (Z)-endoxifen as a potent therapy for hormone receptor-positive breast cancer.
Read more →ATOSAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
Atossa Therapeutics has proposed a Phase 3 clinical study, SMART 2.0, to evaluate the effectiveness of oral (Z)-endoxifen in reducing interval breast cancer among high-risk women. The study aims to leverage advanced mammographic screening techniques and AI risk models. Initial results from a Phase 2 trial suggest that (Z)-endoxifen may significantly lower breast density, enhancing mammogram sensitivity. The company seeks to establish a safer preventive therapy option for women at high risk of breast cancer.
Read more →ATOSAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
Atossa Therapeutics, Inc. has announced the granting of U.S. Patent No. 12,275,684 for enteric oral formulations of (Z)-endoxifen, enhancing its intellectual property portfolio related to breast cancer treatments. This new patent includes claims for oral formulations and methods of treating hormone-dependent disorders, showcasing the company's dedication to innovation in breast cancer therapies. Atossa aims to address unmet medical needs by further developing its proprietary (Z)-endoxifen, which has shown promise in both treatment and prevention of breast cancer. The patent reinforces Atossa's strategic focus on protecting its innovations while contributing to patient solutions.
Read more →ATOSAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Atossa Therapeutics reported its financial results for the full year 2024, highlighting a strong cash position of $71.1 million with no debt. The company is focusing on (Z)-endoxifen, which shows promise in treating metastatic breast cancer, and aims for an efficient regulatory pathway for approval. Operating expenses decreased, but interest income fell slightly, and there was an impairment charge on equity investments.
Read more →ATOSAtossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Atossa Therapeutics will host a conference call on March 25, 2025, to discuss its fourth quarter and full-year 2024 financial results. The call will provide an update on the company's corporate developments and financial performance. Atossa is focused on developing innovative therapies for breast cancer, including its lead candidate, (Z)-endoxifen.
Read more →ATOSAtossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Atossa Therapeutics announced plans to pursue a metastatic breast cancer indication for (Z)-endoxifen, citing an efficient regulatory pathway. The company aims to address the significant unmet need in metastatic breast cancer, where current treatments have limited effectiveness. Encouraging data from early trials supports the drug's potential as a transformative therapy. Atossa also plans to engage with the FDA for additional indications.
Read more →ATOSAtossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Atossa Therapeutics congratulates Dr. Tessa Cigler and Weill Cornell Medicine for receiving a $2.3 million grant from the CDC. This funding will support initiatives to improve access to care and outcomes for young breast cancer patients in New York City. Dr. Cigler will lead efforts to address the unique needs of diverse patient populations.
Read more →ATOSAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Atossa Therapeutics has responded to a PTAB ruling that invalidated claims in U.S. Patent No. 11,572,334, expressing disappointment but noting that it will not appeal the decision. Instead, the company plans to focus on obtaining additional patent protection for its clinical formulations. Additionally, Atossa announced the issuance of a new patent for sustained release compositions of endoxifen.
Read more →ATOSAtossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
Atossa Therapeutics has issued a letter to shareholders highlighting key accomplishments in 2024, particularly the completion of the KARISMA-Endoxifen Phase 2 Study, which showed significant reductions in mammographic breast density. The company is advancing its clinical programs, including the EVANGELINE trial and I-SPY 2 studies, while also expanding its intellectual property portfolio. Looking ahead to 2025, Atossa aims to build on its progress in breast cancer prevention and treatment.
Read more →ATOSAtossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
Atossa Therapeutics has praised the U.S. Surgeon General's Advisory that establishes a significant link between alcohol consumption and breast cancer risk, particularly emphasizing its impact on women's health. The Advisory states that alcohol is a leading preventable cause of cancer, accounting for a substantial number of cases and deaths annually. Atossa's CEO, Dr. Steven Quay, has endorsed the Advisory's recommendations, advocating for public education efforts to sensitize people regarding alcohol's hidden dangers and its role in cancer risk. The company aims to advance therapies targeting breast cancer prevention and increase public policy initiatives supporting this cause.
Read more →ATOSAtossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics, a clinical-stage biopharmaceutical company, will present new data on compounds that show potential synergies with (Z)-endoxifen for breast cancer treatment at the 2024 San Antonio Breast Cancer Symposium. The study utilized insilico and chemical screening methods to identify compounds that can enhance the effects of (Z)-endoxifen, particularly by inhibiting critical cancer pathways. The results indicate that these combinations may lead to improved cell death in breast cancer cells compared to using the drugs in isolation. Further studies are necessary to validate these findings and explore their clinical applications.
Read more →ATOSAtossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Atossa Therapeutics has announced positive results from its Phase 2 KARISMA-Endoxifen trial, showing that low-dose (Z)-endoxifen can significantly reduce mammographic breast density, a critical risk factor for breast cancer. The study involved 240 premenopausal women and demonstrated that both 1 mg and 2 mg doses led to marked reductions in breast density. Importantly, the safety profile of the 1 mg dose was favorable, with no significant adverse events reported compared to placebo. The results will be further discussed during a Poster Spotlight Session at the upcoming 2024 San Antonio Breast Cancer Symposium.
Read more →ATOSAtossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium SEATTLE
Atossa Therapeutics announced that data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium. The trial evaluates (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer. Findings from the trial highlight promising outcomes including target plasma concentrations achieved by a significant portion of participants and strong tumor suppression across dosages. The company plans to proceed with the trial based on the data presented, expecting to initiate recruitment for the next phase in 2025.
Read more →ATOSAtossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Atossa Therapeutics presented research at the AACR Special Conference demonstrating the anti-cancer activity of (Z)-endoxifen and its byproducts, particularly against estrogen receptor-positive (ER+) breast cancer. The study found that compounds AT416E and AT402E exhibited strong anti-proliferative effects and better outcomes than (Z)-endoxifen alone under certain conditions. Future in vivo studies are planned to validate these findings and explore the compounds' clinical applications. The research highlights the potential of these compounds in targeting breast cancers resistant to current therapies.
Read more →ATOSAtossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Atossa Therapeutics is set to present a poster on the anti-cancer effects of (Z)-endoxifen at the AACR Special Conference in Cancer Research. The research focuses on improving efficacy and minimizing side effects of (Z)-endoxifen in treating ERα+ breast cancer. The company is exploring a proprietary formulation of (Z)-endoxifen which has shown promise in early clinical trials. The presentation and ongoing studies are significant due to the potential advancements they could bring to breast cancer treatment.
Read more →ATOSAtossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics announced the acceptance of five abstracts detailing research on (Z)-endoxifen for presentation at the 2024 San Antonio Breast Cancer Symposium. These studies aim to evaluate the drug's effectiveness in breast cancer prevention and treatment, including outcomes from phase 2 trials. Notable topics include the use of (Z)-endoxifen for reducing breast density and assessing quality of life in treated patients. Atossa's innovative formulations and research underline its commitment to enhancing breast cancer therapies.
Read more →ATOSAtossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-e
Atossa Therapeutics reported strong financial results for Q3 2024, highlighting significant progress in its clinical trials for (Z)-endoxifen. The KARISMA-Endoxifen Phase 2 study showed promising reductions in mammographic breast density among participants. Additionally, the preliminary analysis from the I-SPY 2 trial confirmed a high percentage of patients successfully completing treatment and significant decreases in cancer biomarkers. The company's positive trajectory is bolstered by the initiation of a new combination trial and the receipt of a new patent for (Z)-endoxifen compositions.
Read more →ATOSAtossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Atossa Therapeutics has appointed Claudia Lopez as Vice President of Clinical Product Development. With over two decades of experience in clinical development across various therapeutic areas, Lopez previously served at Landos Biopharma. She will focus on advancing Atossa's clinical pipeline, which aims to develop innovative treatments for breast cancer. The CEO expressed confidence in her ability to drive clinical programs and improve outcomes for patients. Atossa continues to emphasize its commitment to addressing significant medical needs in oncology.
Read more →ATOSAtossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTL
Atossa Therapeutics has reported promising results from its KARISMA-Endoxifen Phase 2 trial, which indicated that (Z)-endoxifen effectively reduces mammographic breast density in premenopausal women. Conducted at the Karolinska Institute, the trial showed significant density reductions with low doses of the drug, and it was generally well tolerated. These results may lead to new preventive approaches for breast cancer. Further analysis and detailed results are expected to be shared at the San Antonio Breast Cancer Symposium.
Read more →ATOSAtossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
Atossa Therapeutics has released preliminary analysis results from a Phase 2 I-SPY trial for (Z)-endoxifen, which shows promising efficacy in reducing Ki-67 and functional tumor volume among women with ER+/HER2- breast cancer. In the study, 19 out of 20 participants successfully completed over 75% of the treatment, indicating a strong adherence to the therapeutic regimen. Notably, (Z)-endoxifen achieved a 69% reduction in Ki-67 and a 30.4% decrease in tumor burden after three weeks. The results will be presented at the upcoming RISE UP Breast Cancer Conference, highlighting Atossa’s commitment to innovative treatment options in breast cancer care.
Read more →ATOSAtossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
Atossa Therapeutics is joining forces with Karolinska Institute for a fireside chat at BIO-Europe 2024. The discussion will focus on an AI-based risk model for identifying high-risk patients for breast cancer prevention, supported by the SMART study, which aims to enroll 70,000 women. Atossa's efforts are aimed at validating endoxifen for preventive therapy in breast cancer, addressing a significant unmet medical need. This collaboration demonstrates the company's commitment to advancing oncology research despite the inherent uncertainties in clinical outcomes.
Read more →ATOSAtossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
Atossa Therapeutics, Inc. announced that Michael Parks, the Vice President of Investor and Public Relations, will participate in a virtual fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 16, 2024. The company, which operates in the clinical-stage biopharmaceutical sector, specializes in developing innovative treatments for oncology, particularly breast cancer. Interested individuals can access the conference through a live webcast. Atossa is dedicated to addressing significant unmet medical needs in cancer treatments.
Read more →ATOSAtossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
Atossa Therapeutics recognizes Breast Cancer Awareness Month, advocating for education and innovative treatments in breast cancer care. The company highlights the significance of new FDA regulations regarding breast density notifications to improve early detection. Atossa is leading multiple clinical trials for (Z)-endoxifen, a potential treatment targeting dense breast tissue, and is also involved in a phase 2 study assessing a novel risk assessment model for breast cancer. These efforts aim to enhance screening and treatment options for women affected by breast cancer.
Read more →ATOSAtossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
Atossa Therapeutics has expressed support for the FDA's final rule requiring mammography facilities to notify patients about breast density. This regulation is crucial as breast density is a known risk factor for breast cancer, and informed patients can discuss additional screening options with their healthcare providers. Atossa is actively involved in several clinical studies, particularly with its lead asset, (Z)-endoxifen, which is being evaluated for its potential to address breast cancer prevention and treatment. The company's initiatives align with its mission to enhance early detection and improve patient outcomes in oncology.
Read more →ATOSAtossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Atossa Therapeutics, Inc. will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Steven Quay will take part in a virtual fireside chat and meet with investors, providing opportunities for direct engagement. A recording of the chat will be available on their website for those unable to attend live. The participation in such a significant event highlights Atossa's ongoing development efforts, particularly in oncology.
Read more →ATOSAtossa Therapeutics Granted Additional Patent Protection for Endoxifen
Atossa Therapeutics, Inc. announced that the United States Patent and Trademark Office has granted it a new patent for (Z)-endoxifen compositions and methods. This patent, designated as U.S. Patent No. 12,071,391, expands Atossa's protection for this compound, which is a potent selective estrogen receptor modulator targeted at breast cancer. The company is developing (Z)-endoxifen in various clinical trials, and the new patent is expected to create long-term value for shareholders. Despite the positive news, there are inherent risks related to regulatory approvals and trial outcomes.
Read more →ATOSAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Atossa Therapeutics and Quantum Leap Healthcare Collaborative have initiated their I-SPY 2 trial, marking a key milestone with the dosing of the first patient. This trial will evaluate the combination of Atossa's (Z)-endoxifen with abemaciclib for treating estrogen receptor-positive, HER2-negative breast cancer. A total of 80 participants will be enrolled, focusing on high-risk patients who have limited options due to tumor resistance to traditional therapies. The trial is expected to contribute valuable data by 2026, further supporting the efficacy and safety of this treatment combination.
Read more →ATOSAtossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
Atossa Therapeutics has appointed Michael Parks as Vice President of Investor and Public Relations. With nearly 30 years of experience in corporate communications within the biopharmaceutical field, Parks will enhance the company's communications strategy and investor relations. His background includes leadership roles at PAVmed and Liquidia Corporation, positioning him to advance Atossa's mission in oncology and breast cancer treatments.
Read more →ATOSAtossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update • Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Pha
Atossa Therapeutics announced its Q2 2024 financial results, reporting a strong cash position and significant advances in its clinical trials, particularly the 100% disease control rate observed in patients treated with (Z)-endoxifen in a 24-week trial. The company completed enrollment in multiple cohorts of its ongoing studies and initiated new trials, highlighting their ongoing commitment to addressing unmet medical needs in breast cancer treatment. With an ending cash balance of $79.5 million and no debt, Atossa is well-positioned for future growth and data readouts expected to occur in the coming months.
Read more →ATOSAtossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Atossa Therapeutics has successfully enrolled all participants in the 80mg pharmacokinetic run-in cohort for its Phase 2 EVANGELINE clinical trial. This study evaluates (Z)-endoxifen as a neoadjuvant treatment for ER+/HER2- breast cancer in pre-menopausal women. The results from the previous 40mg cohort demonstrated significant tumor reduction and a favorable safety profile. The trial aims to enroll approximately 175 patients across 25 sites in the United States to assess the efficacy of (Z)-endoxifen compared to standard therapies.
Read more →ATOSAtossa Therapeutics Appoints Heather Rees as Chief Financial Officer
Atossa Therapeutics has appointed Heather Rees as the new Chief Financial Officer, recognizing her valuable contributions over the past seven years. Ms. Rees brings nearly 30 years of financial experience and aims to leverage her insights as Atossa approaches significant data milestones. The company focuses on developing innovative treatments for breast cancer, particularly through its proprietary formulation of (Z)-endoxifen, which has shown promise in clinical studies. Atossa is currently conducting multiple clinical trials assessing the efficacy of (Z)-endoxifen in various breast cancer settings.
Read more →ATOSAtossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer
Atossa Therapeutics announced updated protocol changes for its clinical trial evaluating (Z)-endoxifen in combination with abemaciclib as a neoadjuvant treatment for ER+/HER2- breast cancer. The trial will now administer a higher dose of (Z)-endoxifen, increased from 40 mg to 80 mg daily, based on positive data from the ongoing EVANGELINE study. The study aims to enroll approximately 80 participants, including premenopausal women, to further validate the treatment's efficacy and safety. This updated protocol represents significant advancements in Atossa's development efforts in breast cancer therapies.
Read more →ATOSAtossa Set to Join Russell 3000 Index Effective June 28, 2024
Atossa Therapeutics, Inc. is set to join the Russell 3000 Index effective June 28, 2024, marking a notable advancement for the company. This inclusion is expected to enhance Atossa's visibility and may expand its shareholder base, reinforcing its ongoing clinical development in breast cancer therapeutics, particularly with (Z)-endoxifen. Atossa's CEO highlighted the progress made this year, including the presentation of positive monotherapy data and the initiation of a Phase 2 study with (Z)-endoxifen. However, the company faces uncertainties related to clinical trial outcomes and regulatory approvals.
Read more →ATOSAtossa to Present at the Sidoti Small-Cap Investor Conference
Atossa Therapeutics, Inc. is set to present at the Sidoti Small-Cap Investor Conference on June 12-13, 2024. The presentation will be delivered by Dr. Steven Quay, the company's President and CEO, on June 13 at 9:15 am ET. Atossa is dedicated to developing innovative oncology medicines, particularly focused on breast cancer treatments. A recording of the presentation will be available on Atossa's investor relations page after the event.
Read more →ATOSAtossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
Atossa Therapeutics has announced its support for the SMART study, a Phase 2 clinical trial aimed at validating an artificial intelligence-driven breast cancer risk assessment model. The model is designed to identify women at high risk of developing breast cancer within two years, utilizing advanced imaging techniques and individual risk factors. If successful, it could significantly enhance breast cancer screening methodologies. The study plans to enroll 70,000 women and will include a robust analysis of risk prediction efficacy. Atossa's commitment to this study underscores its focus on improving outcomes in breast cancer prevention and treatment.
Read more →ATOSAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
Atossa Therapeutics has announced the completion of dosing for the last patient in its Phase 2 Karisma-Endoxifen clinical trial. The study examines the efficacy of (Z)-endoxifen in reducing mammographic breast density (MBD) among premenopausal women, an important area given that high MBD is linked to increased breast cancer risk. Atossa aims to share the trial results with regulatory authorities and potentially advance to a Phase 3 study based on these findings. The company is focused on developing (Z)-endoxifen as an innovative treatment for breast cancer prevention and management.
Read more →ATOSAtossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks • Initiated study evalua
Atossa Therapeutics has reported its financial results for Q1 2024 while announcing significant developments in its clinical programs. Notably, the company presented favorable data from the EVANGELINE study showcasing a 100% disease control rate at 24 weeks. Atossa has initiated a study evaluating the combination of (Z)-endoxifen and abemaciclib for ER+/HER2- breast cancer patients. The company ended the quarter with a solid cash position of $84 million and no debt, reflecting stable financial health and ongoing commitment to advancing its innovative therapies.
Read more →ATOSAtossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
Atossa Therapeutics has expressed support for updated breast cancer screening guidelines by the U.S. Preventive Services Task Force, which suggests women start biennial mammograms at age 40. This change responds to rising breast cancer rates and aims to improve timely access to patient care. The company is evaluating its lead drug candidate, (Z)-endoxifen, in multiple Phase 2 trials, focused on reducing breast density, a significant risk factor for breast cancer. Additionally, Atossa is developing a proprietary formulation of (Z)-endoxifen to enhance its therapeutic efficacy and tolerability.
Read more →ATOSAtossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
Atossa Therapeutics has announced an expanded research agreement with Weill Cornell Medicine to investigate the synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Building on previous in silico findings that suggested enhanced anti-tumor effects, the collaboration aims to validate these results in cell culture models before moving to clinical studies. The research will focus on two FDA-approved ADCs in combination with (Z)-endoxifen for treating advanced breast cancer.
Read more →ATOSAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer
Atossa Therapeutics and Quantum Leap Healthcare Collaborative have launched a clinical trial to assess the effectiveness of (Z)-endoxifen combined with abemaciclib in treating women with ER+/HER2- breast cancer. This study will involve approximately 20 patients and aims to explore this combination therapy before surgery. Previous data suggests that (Z)-endoxifen has potential in tumor reduction, providing hope for patients facing high recurrence risks. The ongoing I-SPY 2 trial framework supports the evaluation of novel treatments tailored to specific patient needs.
Read more →ATOSAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Atossa Therapeutics, Inc. announced its participation in the Noble Capital Markets Emerging Growth Healthcare Conference, scheduled for April 17, 2024. CEO Steven Quay will present at the event, which will be accessible virtually. The company is dedicated to developing innovative oncology medicines, particularly for breast cancer, and aims to engage with investors through one-on-one meetings at the conference.
Read more →ATOSAtossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Atossa Therapeutics has presented data from its Phase 2 EVANGELINE clinical trial showing a 100% disease control rate with (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer. The data revealed significant reductions in Ki-67 levels and MRI-documented tumor decreases, indicating effective treatment. Despite some treatment-related toxicities, the results suggest that (Z)-endoxifen could provide a promising neoadjuvant therapy option, potentially improving outcomes for this patient population. Atossa is advancing with a higher dosing regimen in ongoing trials.
Read more →ATOSAtossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 • First patient dosed
Atossa Therapeutics reported its year-end financial results for 2023, highlighting the full enrollment of two Phase 2 studies. Data from both studies is anticipated in the second half of 2024, along with additional findings from the ongoing EVANGELINE study. The company ended the year with $88.5 million in cash and no debt, but also reported an increase in operating expenses compared to the previous year. Atossa aims to accelerate the development of its lead compound, (Z)-endoxifen, for breast cancer prevention and treatment.
Read more →ATOSAtossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Atossa Therapeutics announced a successful five-year treatment update for a patient receiving (Z)-endoxifen under an FDA-approved 'expanded access' program. The patient, diagnosed with ER+/HER2- breast cancer, has remained cancer-free and reported no significant safety concerns during the treatment. This case represents the potential impact of (Z)-endoxifen, which aims to improve outcomes for women with breast cancer, presenting an alternative to existing therapies that may have adverse side effects. Atossa emphasizes the need for innovative treatments given the limitations of current options in managing breast cancer.
Read more →ATOSAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Atossa Therapeutics announced that it has regained compliance with Nasdaq's minimum bid price requirements as of March 15, 2024. The company had previously faced non-compliance due to its stock falling below $1.00 per share but met the necessary trading conditions to restore its status. Atossa is actively developing (Z)-endoxifen, a compound aimed at preventing and treating breast cancer, and is currently engaged in multiple Phase 2 trials to evaluate its effectiveness. The company is optimistic about its ongoing work in oncology, supported by recent positive trial outcomes.
Read more →ATOSAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors SEATTLE
Atossa Therapeutics announced the appointment of Dr. Tessa Cigler, a medical oncologist specializing in breast cancer, to its board of directors. Dr. Cigler brings extensive clinical trial and patient care experience that Atossa hopes to leverage for its (Z)-endoxifen development program. The company is conducting four Phase 2 trials of this investigational treatment, which aims to improve breast cancer prevention and management. Despite the optimism surrounding Dr. Cigler’s appointment, Atossa must navigate potential regulatory hurdles and ensure successful trial progress.
Read more →ATOSAtossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
Atossa Therapeutics has announced the dosing of the first patient with (Z)-endoxifen in the ongoing RECAST DCIS study, aimed at treating Ductal Carcinoma In Situ (DCIS). This Phase 2 trial seeks to investigate the suitability of six months of neoadjuvant endocrine therapy to potentially avoid surgery for many women. The study is poised to challenge the current treatment paradigm which often includes invasive procedures. With the goal of reducing overtreatment, researchers will assess biomarkers alongside new investigational agents.
Read more →ATOSAtossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Atossa Therapeutics has announced the full enrollment of the (Z)-endoxifen arm in its Phase 2 I-SPY 2 clinical trial. This trial focuses on evaluating (Z)-endoxifen as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive invasive breast cancer. The company anticipates data outcomes from the trial in the second half of 2024, which could potentially revolutionize treatment approaches for this patient group. (Z)-endoxifen has shown promise in prior studies, suggesting it may improve tumor resectability and reduce recurrence rates.
Read more →ATOSAtossa Therapeutics Issues Letter to Shareholders
Atossa Therapeutics has provided a shareholder update highlighting significant achievements in 2023. The company is conducting four Phase 2 trials for its (Z)-endoxifen treatment, with results expected later this year. Recent collaborations, specifically with Weill Cornell Medicine, aim to enhance treatment options for aggressive breast cancer. The announcement also notes the impending federal law requiring breast density notifications, which could increase patient discussions about (Z)-endoxifen's impact in lowering breast cancer risks.
Read more →ATOSAtossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
Atossa Therapeutics has appointed Dr. Arezoo Mirad as their Senior Medical Director, bringing extensive experience in oncology development to the team. The company is focused on advancing its (Z)-endoxifen program, which is under investigation in four Phase 2 trials aimed at improving breast cancer treatment. With promising developments expected in 2024, Atossa is positioned favorably in the oncology space despite some regulatory and enrollment challenges ahead. Dr. Mirad expressed her commitment to enhancing the outcomes for patients through this innovative treatment.
Read more →ATOSAtossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
Atossa Therapeutics has successfully completed full enrollment in its Phase 2 Karisma-Endoxifen clinical trial, which aims to assess the efficacy of (Z)-endoxifen in premenopausal women with measurable mammographic breast density. The trial includes 240 participants randomized to receive placebo or varying doses of the drug over a six-month treatment period. The study aims to investigate whether (Z)-endoxifen can reduce breast density, thereby potentially lowering breast cancer incidence rates in high-risk populations. Data from the trial is anticipated to be released in the latter half of 2024.
Read more →ATOSAtossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Atossa Therapeutics announced its Q3 2023 financial results, highlighting significant progress in its Phase 2 clinical trials for (Z)-endoxifen. The company achieved 80% enrollment in two pivotal studies, with data expected in late 2024. Financially, Atossa ended the quarter with $94 million in cash, reflecting careful management of operating expenses. Additionally, the company received approval to conduct a Phase 2 trial in Canada and initiated a new study focused on Ductal Carcinoma In Situ.
Read more →ATOSAtossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
Atossa Therapeutics has appointed Jonathan Finn to its board of directors, effective November 8, 2023. Finn has over 25 years of financial industry experience, particularly in early to mid-stage biotech. His expertise is expected to help accelerate Atossa's growth, especially with critical data readouts and ongoing Phase 2 trials for (Z)-endoxifen. The company aims to innovate treatments for breast cancer while maximizing shareholder value.
Read more →ATOSAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
Atossa Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2023. The event will feature a fireside chat with CEO Steven Quay on September 28th, emphasizing the company's commitment to addressing unmet medical needs in oncology, particularly breast cancer. Interested parties can access a live webcast of the discussion on the company's investor website.
Read more →ATOSAtossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Atossa Therapeutics reported its financial results for Q2 2023, highlighting significant enrollment milestones in ongoing Phase 2 clinical trials for (Z)-endoxifen. The company has expanded its patent protection for (Z)-endoxifen and is entering the Canadian market for clinical trials. Despite a net loss increasing to $9,830, Atossa maintains a solid cash position of $99.4 million to support its ongoing and future studies. The management team was bolstered by the appointment of Greg Weaver as CFO, enhancing the company's strategic direction.
Read more →ATOSAtossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
Atossa Therapeutics, a clinical-stage biopharmaceutical company, will provide a business update and report second quarter 2023 financial results on August 14, 2023. The company has scheduled a conference call for 9:00 a.m. ET the same day to discuss these results. Atossa is focused on developing innovative treatments for significant unmet needs in oncology, particularly breast cancer. The release will include forward-looking statements that outline various associated risks and uncertainties.
Read more →ATOSAtossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
Atossa Therapeutics has received approval from Health Canada to initiate its Phase 2 EVANGELINE clinical trial. This trial will evaluate the effectiveness of (Z)-endoxifen versus standard treatment in premenopausal women with ER+/HER2- breast cancer. The approval allows Atossa to open new clinical sites and enroll patients across Canada, expanding their research capabilities. Data from a pharmacokinetic run-in cohort to establish the optimal dose is expected soon, which could accelerate patient enrollment further.
Read more →ATOSAtossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
Atossa Therapeutics (Nasdaq: ATOS) has reported that 170 patients are currently enrolled in their Phase 2 Karisma-Endoxifen clinical trial, which targets breast density issues in premenopausal women. The study aims to fully enroll by the fourth quarter of 2023 and tests the efficacy of (Z)-endoxifen in reducing mammographic breast density. Notably, there are no approved treatments for women with elevated breast density, underscoring the potential significance of this study. Atossa's (Z)-endoxifen has shown positive preliminary outcomes in early trials and is protected by multiple patents.
Read more →ATOSAtossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
Atossa Therapeutics has entered into a sponsored research agreement with Weill Cornell Medicine to investigate the potential of inducing estrogen receptor expression in triple-negative breast cancer. The study aims to explore whether extracellular vesicles can convert tumors to ER+, thus making them sensitive to treatments like Atossa's Z-endoxifen. This initiative could transform the treatment landscape for patients suffering from this aggressive form of breast cancer, which currently has limited effective options.
Read more →ATOSAtossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics and Quantum Leap Healthcare have announced an update on the enrollment for the (Z)-endoxifen arm in the Phase 2 I-SPY 2 clinical trial. Six patients have already been dosed, with the total target enrollment set at approximately 20 participants. The trial is focused on evaluating (Z)-endoxifen as a neoadjuvant treatment for estrogen receptor-positive breast cancer. This collaborative effort aims to optimize endocrine therapies for patients who may not benefit from traditional chemotherapy.
Read more →ATOSAtossa Therapeutics Announces $10M Stock Repurchase Program
Atossa Therapeutics has announced a $10 million stock repurchase program approved by its Board of Directors, aimed at enhancing long-term value for stockholders. The leadership expresses confidence in the company's prospects and believes the current share price presents a strategic opportunity. The program will involve repurchasing shares in various ways, but execution may be influenced by market conditions and stock performance. Despite the optimistic outlook, the company acknowledges uncertainties related to clinical results and regulatory approvals.
Read more →ATOSAtossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
Atossa Therapeutics, Inc. announced its sponsorship of the Are You Dense MusicFest 2023, aimed at raising awareness about the challenges of dense breast tissue and its link to breast cancer. The festival, taking place on June 24 in Waterbury, Connecticut, is hosted by Are You Dense, Inc., which focuses on educating the public and advocating for better breast cancer screening guidelines. The organization was established to improve awareness of breast health and support legislative changes regarding breast density information in mammogram reports. Atossa’s sponsorship reflects its commitment to addressing significant unmet needs in oncology, particularly concerning breast cancer.
Read more →ATOSAtossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
Atossa Therapeutics, Inc. announced its participation in the upcoming Healthcare Virtual Conference, set for June 21, 2023. CEO Steven Quay and CFO Greg Weaver will discuss the company’s efforts in developing oncology medicines, particularly for breast cancer. The event aims to provide insights into Atossa's strategies and future plans, and a recording will be available afterwards for investor relations purposes. The announcement comes with caution regarding the potential risks and uncertainties that could affect their clinical and regulatory outcomes.
Read more →ATOSAtossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Atossa Therapeutics has announced the completion of enrollment for the pharmacokinetic run-in cohort of its Phase 2 EVANGELINE clinical trial, which evaluates (Z)-endoxifen for treating ER+/HER2- breast cancer. The cohort includes six patients who will receive a daily dosage of 40mg for four weeks to ascertain effective plasma concentration levels. Following this, the treatment cohort will initiate recruitment aimed at healthier candidates for a neoadjuvant treatment lasting up to six months. Results from the trial are anticipated in the third quarter, which will inform the potential optimal dosage and the subsequent progression of the trial.
Read more →ATOSAtossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
Atossa Therapeutics has appointed Greg Weaver as the new Chief Financial Officer, succeeding Kyle Guse. Weaver brings over 30 years of experience in the life sciences industry and has been involved in significant financial strategies, including leading IPOs. He is set to contribute to Atossa’s ongoing Phase 2 clinical trials for breast cancer while helping to advance their product, (Z)-endoxifen. The company emphasizes the importance of this leadership change in its strategy to improve cancer treatment standards.
Read more →ATOSAtossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Atossa Therapeutics has announced its financial results for the first quarter of 2023 and provided updates on its ongoing clinical activities. The company has initiated several Phase 2 trials investigating (Z)-endoxifen for treating breast cancer, with full enrollment of one study expected by the end of the year. Atossa reported ending the first quarter with $103.9 million in cash and cash equivalents, maintaining a debt-free balance sheet. The company has also secured additional patent protection for its drug formulation.
Read more →ATOSAtossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Atossa Therapeutics, Inc. has announced it will present a Trial in Progress poster for its Phase 2 clinical study of (Z)-endoxifen at the 2023 ASCO Annual Meeting. This study focuses on premenopausal women with early stage ER+/HER2- breast cancer. (Z)-endoxifen is being compared to the current standard of care in a randomized non-inferiority trial. Full details of the presentation will be available on May 25, 2023, ahead of the meeting scheduled for June 4, 2023.
Read more →ATOSAtossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”
Atossa Therapeutics, Inc. has announced that its CEO, Steven Quay, will participate in a public webinar discussing the clinical development of the drug (Z)-endoxifen, which is under investigation for breast cancer treatment. The event, scheduled for May 4, 2023, will allow the public to engage by submitting questions in advance. Atossa is exploring (Z)-endoxifen as a potentially safer, oral formulation that does not require liver metabolism, and it is currently in multiple Phase 2 trials. However, the company also faces uncertainties regarding regulatory approvals and clinical trial enrollments.
Read more →ATOSAtossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
Atossa Therapeutics has announced its financial results for the year ended December 31, 2022, detailing significant advancements in its clinical programs. The company reported the initiation of the Phase 2 EVANGELINE study, alongside progress in the Karisma-Endoxifen study and a new arm in the I-SPY 2 trial, all aimed at addressing unmet needs in breast cancer treatment. However, Atossa continues to face challenges, including no sustainable revenue and a marked increase in operating expenses. The company's strong commitment to innovation in oncology is underscored by recent investments and the expansion of its patent portfolio.
Read more →ATOSAtossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, in collaboration with Quantum Leap Healthcare, has announced a new study arm evaluating (Z)-endoxifen in the ongoing I-SPY 2 clinical trial. This trial focuses on developing novel treatments for premenopausal women with ER+ invasive breast cancer, addressing the need for more effective therapies with fewer side effects. Approximately 20 patients will be administered (Z)-endoxifen for up to 24 weeks before surgery. The results are anticipated to complement existing data from Atossa's ongoing Phase 2 trials, showcasing the drug's potential in enhancing treatment outcomes for this patient demographic.
Read more →ATOSAtossa to Present at the Sidoti Small-Cap Virtual Conference
Atossa Therapeutics, Inc. has announced its participation in the Sidoti Small-Cap Virtual Conference, scheduled for March 22-23, 2023. Executives Dr. Steven Quay and Kyle Guse will present on March 23 at 1:00 pm ET. This engagement highlights Atossa's focus on innovative medicines for significant unmet medical needs in cancer, particularly breast cancer. Following the event, a recording of the presentation will be available on their investor relations page.
Read more →ATOSAtossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
Atossa Therapeutics has commenced its Phase 2 EVANGELINE study, dosing the first patient with (Z)-endoxifen for premenopausal women with ER+/HER2- breast cancer. This trial aims to evaluate the efficacy of (Z)-endoxifen compared to the standard treatment of exemestane and goserelin. The primary outcome will measure the endocrine sensitive disease rate using Ki-67 after four weeks of treatment. With approximately 175 patients expected to enroll, the study represents a significant step in addressing the need for more effective therapies in this patient group.
Read more →ATOSAtossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen
Atossa Therapeutics has announced the granting of a new patent by the US Patent and Trademark Office for its oral formulation of (Z)-endoxifen in enteric capsules. This patent adds to the company’s intellectual property portfolio and highlights the unique delivery method intended to enhance treatment efficacy for breast cancer patients. The company is currently conducting Phase 2 trials to assess the safety and effectiveness of (Z)-endoxifen in treating ER+/HER2- breast cancer and addressing elevated mammographic breast density. These developments position Atossa as a key player in offering alternatives for patients with limited treatment options.
Read more →ATOSAtossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, is pleased to announce the appointment of Eric Van Zanten as Vic
Read more →ATOSAtossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seek
Read more →ATOSAtossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy
SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop in
Read more →ATOSAtossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.
SEATTLE, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and adjunctive tre
Read more →ATOSAtossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
SEATTLE, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer, announced today th
Read more →ATOSAtossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast ca
Read more →ATOSAtossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast can
Read more →ATOSAtossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announc
Read more →ATOSAtossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus o
Read more →ATOSAtossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on
Read more →ATOSAtossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announce
Read more →ATOSAtossa Therapeutics to Present at the Q2 Investor Summit Conference
SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast c
Read more →ATOSAtossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharma
Read more →ATOSAtossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that man
Read more →ATOSAtossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that the
Read more →ATOSAtossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financia
Read more →ATOSAtossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast ca
Read more →ATOSAtossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast ca
Read more →ATOSAtossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast can
Read more →ATOSAtossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
SEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announc
Read more →ATOSAtossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announc
Read more →ATOSAtossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious disea
Read more →ATOSAtossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focu
Read more →ATOSAtossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor Atossa establishes intended criteria for non-use of additional shares for financing transactions SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage bio
Read more →ATOSAtossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus
Read more →ATOSAtossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announ
Read more →ATOSAtossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus
Read more →ATOSAtossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmac
Read more →ATOSAtossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
SEATTLE, June 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces th
Read more →ATOSAtossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces th
Read more →ATOSAtossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021
SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that
Read more →ATOSAtossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announc
Read more →ATOSAtossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1:00 PM Pacific Time
SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases urges stockholders to
Read more →ATOSAtossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021
SEATTLE, April 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced th
Read more →ATOSAtossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced th
Read more →ATOSAtossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update
SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today annou
Read more →ATOSAtossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market
SEATTLE, March 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious
Read more →ATOSAtossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases today announced the
Read more →ATOSAtossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focu
Read more →ATOSAtossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
SEATTLE, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical needs in oncology and infectious diseases, with a current foc
Read more →ATOSAtossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, annou
Read more →ATOSAtossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early
SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants
SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, annou
Read more →ATOSAtossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021
SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, annou
Read more →ATOSAtossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on brea
Read more →ATOSAtossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market
SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on brea
Read more →ATOSAtossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering
SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, anno
Read more →ATOSAtossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020
SEATTLE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, tod
Read more →ATOSAtossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, tod
Read more →ATOSAtossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, tod
Read more →ATOSAtossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020
SEATTLE, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19
SEATTLE, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
SEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19
SEATTLE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
SEATTLE, July 30, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, anno
Read more →ATOSAtossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program
SEATTLE, July 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, anno
Read more →ATOSAtossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, toda
Read more →ATOSAtossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls
SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, anno
Read more →ATOSAtossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201
SEATTLE, June 11, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, anno
Read more →ATOSAtossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study
SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, annou
Read more →ATOSAtossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
SEATTLE, May 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Receives FDA Feedback on Two Ongoing Programs
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today
Read more →ATOSAtossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study
SEATTLE, April 27, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced that it has contracted with NYC Health
Read more →ATOSAtossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 patients on mechanical ventilation. AT-H201 is a novel formulation of two pharmaceu
Read more →ATOSAtossa Therapeutics Launches COVID-19 HOPE Drug Development Program
SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced a new drug development program called
Read more →ATOSAtossa Therapeutics Announces Clinical Progress
SEATTLE, April 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced recent progress with its Phase 2
Read more →ATOSAtossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update
SEATTLE, March 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the fourth
Read more →ATOSAtossa Therapeutics Announces Upcoming Meeting with FDA
SEATTLE, March 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that it will meet with the U.S. FDA on
Read more →ATOSAtossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density
SEATTLE, March 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has filed with the Swedish Med
Read more →ATOSAtossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
SEATTLE, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO will present a corp
Read more →ATOSAtossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020
SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our Valued Shareholders: I begin this letter with a sense of great pride about our accompl
Read more →ATOSAtossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
SEATTLE, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that its corporate name change from "At
Read more →ATOSAtossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has contracted with Stockholm South
Read more →ATOSAtossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019
SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured pres
Read more →ATOSAtossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update
SEATTLE, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the third quarte
Read more →ATOSAtossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO and General Counsel of A
Read more →ATOSAtossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology
SEATTLE and ENCINO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research Foundatio
Read more →ATOSAtossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen
SEATTLE, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary results from its Phase 1 study o
Read more →ATOSAtossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference
SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO and General Counsel of
Read more →ATOSAtossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet
SEATTLE, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all participant activities have been c
Read more →ATOSAtossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update
SEATTLE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the second quart
Read more →ATOSAtossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk
SEATTLE, July 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced the online launch of company CEO Steven Quay
Read more →ATOSAtossa Genetics Provides Information on FDA Expanded Access Policy and Requests
SEATTLE, July 17, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported that patients and their doctors can now visit
Read more →ATOSAtossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated
SEATTLE, July 11, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it is developing a new proprietary modi
Read more →ATOSAtossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
SEATTLE, June 27, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary analysis from its recentl
Read more →ATOSAtossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019
SEATTLE, May 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured pres
Read more →ATOSAtossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update
SEATTLE, May 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the quarter ended
Read more →ATOSAtossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit
SEATTLE, April 25, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven C. Quay, M.D., Ph.D., Atossa’s
Read more →ATOSAtossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019
SEATTLE, April 22, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Steven C. Quay, M.D., Ph.D., Atossa’s
Read more →ATOSAtossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
SEATTLE, March 28, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced year end 2018 financial results and pr
Read more →ATOSAtossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
SEATTLE, March 26, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the Institutional Review Board (
Read more →ATOSAtossa Genetics Announces Receipt of $10 Million
SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it rec
Read more →ATOSAtossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Pr
Read more →ATOSAtossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
SEATTLE, Feb. 07, 2019 (GLOBE NEWSWIRE) -- , February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today updated t
Read more →ATOSAtossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force
SEATTLE, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has provided suggested changes
Read more →ATOSAtossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019
SEATTLE, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our Valued Shareholders: I begin this letter with a sense of great pride about our accomplishme
Read more →ATOSAtossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen
SEATTLE, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported final results from its Phase 1 dose-escalation stud
Read more →ATOSAtossa Genetics Announces FDA Approval of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
SEATTLE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has approved an “expanded
Read more →ATOSAtossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update
SEATTLE, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced third quarter ended September 30, 2018
Read more →ATOSAtossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density
SEATTLE, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, has completed enrollment in its Phase 2 study of Atossa’s pr
Read more →ATOSAtossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen ***All Objectives Successfully Met*** Conference Call to Be Held Today at 10 am Eastern Time SEATTLE
Atossa Genetics Announces Preliminary Male Phase 1 Study of Topical ***All Objectives Successfully Met*** Conference Call to Be Held Today at 10 SEATTLE, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company develop
Read more →ATOSAtossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT
SEATTLE, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am
Read more →ATOSAtossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update SEATTLE
Genetics Announces Second Quarter 2018 Financial Results Provides Company Update August 13, 2018 -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast condit
Read more →ATOSAtossa Genetics Contracts with Additional Manufacturer of Endoxifen
SEATTLE, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that is has added
Read more →ATOSAtossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program
SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advanci
Read more →ATOSAtossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer
SEATTLE, July 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened a
Read more →ATOSAtossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density
SEATTLE, June 26, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened it
Read more →ATOSAtossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men
SEATTLE, June 20, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed
Read more →ATOSAtossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board
SEATTLE, June 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the appointmen
Read more →ATOSAtossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering
NEW YORK, May 25, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. ("Atossa" or "the Company") announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, May 24, 2018 and these rights are no longer exercisable. The Company ac
Read more →ATOSAtossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has rec
Read more →ATOSAtossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update SEATTLE
Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update SEATTLE, May 14, 2018 -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other
Read more →ATOSAtossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT
SEATTLE, May 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced it will host a
Read more →ATOSAtossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services’ Office on Women’s Health
SEATTLE, May 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced its support of
Read more →ATOSAtossa Genetics Regains NASDAQ Compliance
SEATTLE, May 08, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has rec
Read more →ATOSAtossa Genetics Reminds Investors of Today’s Deadline to be a Shareholder of Record
- To be a shareholder of record, investors are advised to own Atossa stock by 4:00 PM ET, Monday, May 7, 2018 to account for two-day settlement - Record date set as May 9, 2018 SEATTLE, May 07, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a
Read more →ATOSAtossa Genetics Forms Strategic Advisory Board to Accelerate Growth
SEATTLE, May 03, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the formation o
Read more →ATOSAtossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study
SEATTLE, April 30, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced today that it has r
Read more →ATOSAtossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men
SEATTLE, April 24, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received
Read more →ATOSAtossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
SEATTLE, April 23, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today provided an informational update to
Read more →ATOSAtossa Genetics Announces 1 for 12 Reverse Stock Split
SEATTLE, April 20, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced a reverse split of its common stock at a ratio
Read more →ATOSAtossa Genetics Requests Shareholders to Vote
SEATTLE, April 16, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, urges shareholders to vote on two of our most recent proposals
Read more →ATOSAtossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male Subjects
SEATTLE, April 12, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that is has fully enrolled the first of three
Read more →ATOSAtossa Genetics Appoints Per Hall, MD, Ph.D. as Scientific Advisor
SEATTLE, March 27, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions today announced that Per Hall, MD, Ph.D., has been appointed as
Read more →ATOSAtossa Genetics Launches Mens’ Breast Health Program
SEATTLE, March 22, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has expanded its breast health program
Read more →ATOSAtossa Genetics Announces 2017 Financial Results and Provides Company Update SEATTLE
Financial Results and Provides Company Update March 8, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announces 2017 fin
Read more →ATOSNASDAQ: ATOS WWW . ATOSSAGENETICS . COM 2018 A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED . C ORPORATE P RESENTATION F EBRUARY 21, 2018 2 Some of the information presented herein may contain projections or other for
1 NASDAQ: ATOS WWW . ATOSSAGENETICS . COM 2018 A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED . C ORPORATE P RESENTATION F EBRUARY 21, 2018 2 Some of the information presented herein may contain projections or other forward - looking statements regarding future events or the
Read more →ATOSAtossa Genetics to Present at Adoptive T-Cell Therapy Symposium - Molecular Medicine Tri-Conference on Thursday February 15, 2018
SEATTLE, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it will deliver an invited presentation on
Read more →ATOSAtossa Genetics Presents Additional Findings from its Phase 1 Study of Oral Endoxifen Conference Call Today at 4:30 pm
Atossa Genetics Presents Additional Findings from its Phase 1 Study of Oral Endoxifen Conference Call Today at 4:30 pm EST SEATTLE, February 1, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics
Read more →ATOSAtossa Genetics to Host Conference Call to Present Additional Findings from its Phase 1 Study of Oral Endoxifen Thursday February 1, 2018 at 4:30 pm EST
SEATTLE, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today it will host a conference call on February 1, 2
Read more →ATOSAtossa Genetics President and CEO Issues Letter to Stockholders Highlighting Key Accomplishments and Outlines Milestones for 2018
SEATTLE, Dec. 28, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) today announced it has issued the following letter by Dr. Steven C. Quay, President and CEO, to Atossa stockholders: Dear Valued Stockholders: Over the past two years, we have transformed Atossa into
Read more →ATOSAtossa Genetics Appoints Carl Novina, MD, PhD as Scientific Advisor
SEATTLE, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions today announced that Carl Novina, MD
Read more →ATOSAtossa Genetics Announces Pricing of $1.4 Million Registered Direct Offering
SEATTLE, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today it has entered into
Read more →ATOSAtossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company Update SEATTLE
Genetics Announces Third Quarter 2017 Financial Results And Provides Company Update November 14, 2017 - Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer a
Read more →ATOSAtossa Genetics Applauds Newly-Introduced Federal Legislation Requiring That Breast Density Be Reported To Physicians and Patients
SEATTLE, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced its support of proposed federal legislation tha
Read more →ATOSAtossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment Option
SEATTLE, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today the closing of its
Read more →ATOSAtossa Genetics Announces Pricing of $5.1 Million Public Offering of Common Stock SEATTLE
Genetics Announces Pricing of $5.1 Million Public Offering of Common Stock Oct. 26, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and
Read more →ATOSAtossa Genetics Announces Preliminary Results from Phase 1 Study of Oral Endoxifen All Objectives Successfully Met Conference Call To Be Held Today at 10 am Eastern Time SEATTLE
Atossa Genetics Announces Preliminary Results Phase 1 Study of Oral Endoxifen All Objectives Successfully Met Conference Call To Be Held Today at 10 am SEATTLE, October 25, 2017 -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel
Read more →ATOSAtossa Genetics Announces Proposed Public Offering of Common Stock
SEATTLE, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that it intends to
Read more →ATOSAtossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Oral Endoxifen Wednesday, October 25, 2017 at 10 am EDT
SEATTLE, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today it will host a conference call on October 25, 2
Read more →ATOSAtossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter Technology
SEATTLE, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that the Ernest Mario School of Pharmacy at Rutgers,
Read more →ATOSAtossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer
SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today a new program using Chimeric Antigen Receptor Therap
Read more →ATOSAtossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017
SEATTLE, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured presen
Read more →ATOSAtossa Genetics Announces Upcoming Phase 2 Study of Topical Endoxifen
SEATTLE, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions has contracted with a leading European hospital to conduct a Ph
Read more →ATOSAtossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen ***All Objectives Successfully Met*** Conference Call To Be Held Today at 2pm Eastern Time SEATTLE
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen ***All Objectives Successfully Met*** Call To Be Held Today at 2pm Eastern Time SEATTLE, September 14, 2017 -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company
Read more →ATOSAtossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDT
SEATTLE, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today it will host a conference call on September 14
Read more →ATOSAtossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update SEATTLE
Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update August 14, 2017 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced Second Quarter ended June 30, 2017 financial results and provided an update on recent company developments. Quay, Presid
Read more →ATOSAtossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study
SEATTLE, July 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, has now completed enrollment in its Phase 1 dose escalation stu
Read more →ATOSAtossa Genetics Announces First Quarter
Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update SEATTLE, May 11, 2017 - Atossa Genetics Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2017 financial results and provided an update on recent company developments.
Read more →ATOSOT3 - 02 - 08: Open label, phase 2 safety, efficacy, and pharmacokinetic study of pre - surgical intramuscular and intraductal fulvestrant in wom en with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy
OT3 - 02 - 08: Open label, phase 2 safety, efficacy, and pharmacokinetic study of pre - surgical intramuscular and intraductal fulvestrant in wom en with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy Sheldon Marc Feldman M.D. FACS; Chief, Division of Breast S
Read more →ATOSAtossa Genetics Announces Third Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Monday
Atossa Genetics Announces Third Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Monday, November 14, 2016 at 5:30pm Eastern Time SEATTLE, November 14, 2016 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced Third Quarter ended Septe
Read more →ATOSAtossa Genetics, Inc. Prices Underwritten Public Offering of 1,150,000 Common Shares SEATTLE, WA - (Marketwired) - 08/31/16 - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public of
Genetics, Inc. Prices Underwritten Public Offering of 1,150,000 Common Shares SEATTLE, WA - (Marketwired) - 08/31/16 - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock at a price to the
Read more →ATOSAtossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Monday
Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Monday August 15, 2016 at 4:30 pm Eastern Time SEATTLE, August 12, 2016 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced Second Quarter ended June 30
Read more →ATOSNASDAQ: ATOS WWW . ATOSSAGENETICS . COM 2016, A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED . C ORPORATE P RESENTATION J ULY 27, 2016 2 Some of the information presented herein may contain projections or other forwar
1 NASDAQ: ATOS WWW . ATOSSAGENETICS . COM 2016, A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED . C ORPORATE P RESENTATION J ULY 27, 2016 2 Some of the information presented herein may contain projections or other forward - looking statements regarding future events or the fut
Read more →ATOSAtossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement with Aspire Capital Fund, LLC SEATTLE, WA
Atossa Genetics Announces $10 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC SEATTLE, WA -- May 27, 2016 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LL
Read more →ATOSEX-10.1 2 v440599_ex99-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this " Agreement ") is made and entered into as of
AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of May 18, 2016 (the "Effective Date") by and between Kyle Guse, an individual ("Employee"), and Atossa Genetics Inc. a Delaware corporation,
Read more →ATOSAtossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 pm Eastern Time SEATTLE
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 SEATTLE, May 5, 2016 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2016 financial results and provided a
Read more →ATOSAtossa Genetics Announces 2015 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 pm Eastern Time SEATTLE
Atossa Genetics Announces 2015 Financial and Provides Company Update Conference Call to be Held Today at 4:30 SEATTLE, March 30, 2016 - Atossa Genetics Inc. (NASDAQ: ATOS) today announced 2015 financial results and provided an update on recent company developments. Steve Qua
Read more →ATOSAtossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 pm Eastern Time SEATTLE
Genetics Announces Third Quarter 2015 Financial Results Provides Company Update Conference Call to be Held Today at 4:30 SEATTLE, November 12, 2015 - Atossa Genetics Inc. (NASDAQ: ATOS) today announced third quarter 2015 financial results and provided an update on recent comp
Read more →ATOSAtossa Genetics Inc. Announces Appointment of Scott Youmans as Chief Operating Officer Seattle, Washington
Atossa Genetics Inc. Announces Appointment of Scott Youmans as Chief Operating Officer Seattle, Washington - September 2, 2015 - Atossa Genetics Inc. (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat b
Read more →ATOSAnnounces Second Quarter 2015 Financial Results
Announces Second Quarter 2015 Financial Results Revenue for Q2 2015 of $2.7 Million Conference Call to be Held Today at 4:30 SEATTLE, August 6, 2015 - Atossa Genetics Inc. (NASDAQ: ATOS) today announced second quarter 2015 financial results and provided an update on recent co
Read more →ATOSAtossa Genetics Inc. to Raise Approximately $6,220,000 from Institutional Healthcare Investors Seattle, Washington
Atossa Genetics Inc. to Raise Approximately $6,220,000 from Institutional Healthcare Investors Seattle, Washington - June 5, 2015 - Atossa Genetics Inc. (Nasdaq: ATOS) (the "Company" or "Atossa") today announced it priced an offering to raise approximately $6,220,000 through
Read more →ATOSCommon Stock Purchase Agreement
Atossa Genetics Announces $25 Million At-The-Market Common Stock Purchase Agreement SEATTLE, WA - May 28, 2015 - Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has entered into a $25 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of
Read more →ATOSAtossa Genetics Announces First Quarter 2015 Financial Results and Provides Company Update Achieves Total Revenue for Q1 2015 of $1.9 Million Conference Call to be Held Today at 4:30 pm Eastern Time SEATTLE
Atossa Genetics Announces First Quarter 2015 Financial Results and Provides Company Update Achieves Total Revenue for Q1 2015 of Conference Call to be Held Today at 4:30 SEATTLE, May 13, 2015 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced first quarter 2015 financia
Read more →ATOSAtossa Genetics Announces 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 pm Eastern Time SEATTLE
Atossa Genetics Announces 2014 Financial and Provides Company Update Conference Call to be Held Today at 4:30 SEATTLE, March 30, 2015 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced 2014 financial results and provided an update on recent company developments. Steve Q
Read more →ATOSThe Breast Care Company NASDAQ: ATOS WWW .
1 The Breast Care Company NASDAQ: ATOS WWW . ATOSSAGENETICS . COM J ANUARY 13, 2015 2015, A TOSSA G ENETICS , I NC . A LL R IGHTS R ESERVED . 2 Some of the information presented herein may contain projections or other forward - looking statements regarding future events or the f
Read more →ATOSAtossa Genetics Announces Third Quarter 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 pm Eastern Time SEATTLE
Atossa Genetics Announces Third Quarter 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:30 SEATTLE, November 12, 2014 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced Third Quarter 2014 financial results and provided an update
Read more →ATOSAtossa Genetics Inc. Provides Regulatory and Commercial Update on its ForeCYTE Breast Aspirator and its FullCYTE Breast Aspirator Investor Call Scheduled for
Atossa Genetics Inc. Provides Regulatory Update on its ForeCYTE Breast Aspirator and its FullCYTE Breast Aspirator Investor Call Scheduled for September 24, 2014 at 9:00 am EDT SEATTLE - September 23, 2014 - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that the U.S.
Read more →ATOSAtossa Genetics Announces Second Quarter 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:45 pm Eastern Time SEATTLE
Atossa Genetics Announces Second Quarter 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:45 SEATTLE, August 12, 2014 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced Second Quarter 2014 financial results and provided an update
Read more →ATOSAtossa Genetics Adopts Stockholder Rights Agreement SEATTLE
Atossa Genetics Adopts Stockholder Rights SEATTLE, May 22, 2014 - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that its Board of Directors has approved the adoption of a stockholder rights agreement. The stockholder rights agreement is designed to deter coercive, unfair
Read more →ATOSAtossa Genetics Announces First Quarter 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:45 pm Eastern Time SEATTLE
Atossa Genetics Announces First Quarter 2014 Financial Results and Provides Company Update Conference Call to be Held Today at 4:45 SEATTLE, May 14, 2014 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced First Quarter 2014 financial results and provided an update on re
Read more →ATOSAtossa Genetics Announces 2013 Financial Results and Provides Company Update Conference Call to be Held Today at 4:45 pm Eastern Time SEATTLE
Atossa Genetics Announces 2013 Financial and Provides Company Update Conference Call to be Held Today at 4:45 SEATTLE, March 27, 2014 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced 2013 financial results and provided an update on recent corporate developments. "With
Read more →ATOSLICENSE AND SERVICES AGREEMENT This License and Services Agreement (" Agreement ") is made and entered into as of
License and Services Agreement ("Agreement") is made and entered into as of June 10, 2013 (the "Effective Date") by and between A5 Genetics KFT, Corporation with its principal place of business at Gerecse u. 16, H-2094, Hungary ("A5"), and Atossa Genetics Inc., a Delaware corpo
Read more →ATOSAtossa Genetics Reports Third Quarter 2013 Results and Provides Company Update Announces Second Common Stock Purchase Agreement with Aspire Capital for up to $25 Million Seattle
Atossa Genetics Reports Third Quarter 2013 Results and Provides Company Update Announces Second Common Stock Purchase Agreement with Aspire Capital for up to $25 Million Seattle, November 12, 2013 - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company , today anno
Read more →ATOSMedical Device Voluntary Recall - News Release ForeCYTE Breast Health Test; Mammary Aspiration Specimen Cytology Test (MASCT) FOR IMMEDIATE RELEASE
Medical Device Voluntary Recall - News ForeCYTE Breast Health Test; Mammary Aspiration Specimen Cytology Test (MASCT) FOR IMMEDIATE RELEASE: October 4, 2013 1616 EastLake Ave East, Suite 510 www.atossagenetics.com On October 4, 2013 Atossa Genetics Inc. (NASDAQ: ATOS) init
Read more →ATOSAtossa Genetics Reports Second Quarter 2013 Results and Operating Highlights Second Quarter Revenue Up 46%; Year-to-date Revenue Up 83% over Prior Year Seattle
Atossa Genetics Reports Second Quarter 2013 Results and Operating Highlights Second Quarter Revenue Up 46%; Year-to-date Revenue Up 83% over Prior Year Seattle, August 14, 2013 -- Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company , today announced its second qu
Read more →ATOSAtossa Genetics Announces National Agreement with Network Provider FedMed More Than 40 Million Americans Have Access to FedMed's National Provider Network SEATTLE, WA
Atossa Genetics Announces National Agreement with Network Provider FedMed Million Americans Have Access to FedMed's National Provider Network SEATTLE, WA - March 13, 2013 - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company , has entered into a contractual agreem
Read more →ATOSAtossa Genetics Announces Third Quarter 2012 Financial Results Prepares for National Roll Out of ForeCYTE Breast Health Test for Breast Cancer Risk Assessment SEATTLE
Atossa Genetics Announces Third Quarter 2012 Financial Results Prepares for National Roll Out of ForeCYTE Breast Health Test for Breast Cancer Risk Assessment SEATTLE, December 20, 2012 - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced financial results for the third q
Read more →Competitive Position
How ATOS ranks across every disease it competes inCompetitive Position is a premium feature
See how ATOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial